Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Medical uses  





2 History  





3 Society and culture  



3.1  Names  







4 Research  





5 References  





6 Further reading  














Bimekizumab






Français
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Bimekizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetIL17A, IL17F, IL17AF
Clinical data
Trade namesBimzelx
Other namesUCB4940, bimekizumab-bkzx
License data
Pregnancy
category
  • Routes of
    administration
    Subcutaneous
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)[1]
  • CA: ℞-only / Schedule D[3][4]
  • US: ℞-only[5]
  • EU: Rx-only[6]
  • Identifiers
    CAS Number
    DrugBank
    UNII
    KEGG
    Chemical and physical data
    FormulaC6552H10132N1750O2029S42
    Molar mass147229.87 g·mol−1

    Bimekizumab, sold under the brand name Bimzelx, is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody[6][7] that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.[6]

    The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat).[6] Injection site reactions were also common, reported in 3% of subjects.[8]

    Bimekizumab was approved for medical use in the European Union in August 2021,[6][9][10] and in the United States in October 2023.[11][12]

    Medical uses

    [edit]

    In the EU, bimekizumab is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, non-radiographic axial spondyloarthritis, and active ankylosing spondylitis.[6]

    History

    [edit]

    Bimekizumab is being developed by Belgian pharmaceutical company UCB.[citation needed]

    Society and culture

    [edit]

    Names

    [edit]

    Bimekizumab is the international nonproprietary name (INN).[13]

    Research

    [edit]

    Phase III trials have demonstrated that bimekizumab is superior to not only adalimumab[14] but also secukinumab[15] and ustekinumab[16] for the treatment of plaque psoriasis.

    References

    [edit]
    1. ^ a b "Bimzelx APMDS". Therapeutic Goods Administration (TGA). 7 April 2022. Archived from the original on 24 April 2022. Retrieved 24 April 2022.
  • ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Archived from the original on 3 April 2022. Retrieved 2 January 2023.
  • ^ "Bimzelx Product information". Health Canada. 25 April 2012. Archived from the original on 29 June 2022. Retrieved 29 June 2022.
  • ^ "Regulatory Decision Summary for Bimzelx". Drug and Health Products Portal. 23 February 2024. Retrieved 1 April 2024.
  • ^ "Bimzelx- bimekizumab injection, solution". DailyMed. 20 October 2023. Retrieved 10 November 2023.
  • ^ a b c d e f "Bimzelx EPAR". European Medicines Agency (EMA). 23 June 2021. Archived from the original on 25 August 2021. Retrieved 24 August 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  • ^ Lim SY, Oon HH (13 May 2019). "Systematic review of immunomodulatory therapies for hidradenitis suppurativa". Biologics: Targets & Therapy. 13: 53–78. doi:10.2147/BTT.S199862. PMC 6526329. PMID 31190730.
  • ^ FDA Professional Drug Information
  • ^ "Bimzelx Product information". Union Register of medicinal products. Archived from the original on 4 March 2023. Retrieved 3 March 2023.
  • ^ "UCB Announces European Commission Approval of Bimzelx (bimekizumab) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis". UCB (Press release). 24 August 2021. Archived from the original on 25 August 2021. Retrieved 24 August 2021.
  • ^ Frellick M (18 October 2023). "FDA Approves Bimekizumab for Plaque Psoriasis in Adults". Medscape. Archived from the original on 28 October 2023. Retrieved 28 October 2023.
  • ^ "Bimzelx Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis". UCB (Press release). 18 October 2023. Archived from the original on 28 October 2023. Retrieved 28 October 2023.
  • ^ World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 72". WHO Drug Information. 28 (3). hdl:10665/331112.
  • ^ Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, et al. (July 2021). "Bimekizumab versus Adalimumab in Plaque Psoriasis". The New England Journal of Medicine. 385 (2): 130–141. doi:10.1056/NEJMoa2102388. PMID 33891379. S2CID 233372177.
  • ^ Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, et al. (July 2021). "Bimekizumab versus Secukinumab in Plaque Psoriasis". The New England Journal of Medicine. 385 (2): 142–152. doi:10.1056/NEJMoa2102383. PMID 33891380. S2CID 233370455.
  • ^ Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, et al. (February 2021). "Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial". Lancet. 397 (10273): 487–498. doi:10.1016/S0140-6736(21)00125-2. PMID 33549193. S2CID 231809826.
  • Further reading

    [edit]
    • Reis J, Vender R, Torres T (August 2019). "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis". BioDrugs. 33 (4): 391–399. doi:10.1007/s40259-019-00361-6. PMID 31172372. S2CID 174812750.

    Retrieved from "https://en.wikipedia.org/w/index.php?title=Bimekizumab&oldid=1234853209"

    Category: 
    Monoclonal antibodies
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Use dmy dates from June 2023
    Drugs with non-standard legal status
    Articles without EBI source
    Chemical pages without ChemSpiderID
    Articles without InChI source
    Articles containing unverified chemical infoboxes
    Drugs that are a monoclonal antibody
    All articles with unsourced statements
    Articles with unsourced statements from June 2023
     



    This page was last edited on 16 July 2024, at 13:36 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki